semaglutide and renal failure in patients with overweight or obesity chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial Kidney and Survival Benefits of

US research on mice and rats has suggested semaglutide the powerful ingredient behind Wegovy could raise the risk of medullary thyroid cancer (MTC)

The pivotal trial randomized 412 HIV-infected patients with abdominal fat accumulation to 2 mg of subcutaneous tesamorelin daily or placebo for 26 weeks, in a double-blind, placebo-controlled design

Encourage your congress person to support the Treat and Reduce Obesity Act which would eliminate this old language and allow proper coverage determinations

Stacking MOTS-C with Retatrutide is relatively straightforward, but these common pitfalls can derail an otherwise well-designed protocol